Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To better understand the physiologic excretion and/or catabolism of circulating peripheral amyloid beta (Abeta), we labeled human Abeta40 (monomeric, with predominant unordered structure) and Abeta42 (mixture of monomers and oligomers in approximately 50:50 ratio, rich in beta-sheet conformation) with either Na(125)I or (125)I-tyramine cellobiose, also known as the cell-trapping ligand procedure, testing their blood clearance and organ uptake in B6SJLF1/J mice. Irrespective of the labeling protocol, the peptide conformation, and the degree of oligomerization, both Abeta40 and Abeta42 showed a short half-life of 2.5-3.0 min. The liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide uptake, followed by the kidney. In vivo, hepatocytes captured >90% of the radiolabeled peptides which, after endocytosis, were preferentially catabolized and excreted into the bile. Biliary excretion of intact as well as partially degraded Abeta species became obviously relevant at doses above 10 microg. The use of biotin-labeled Abeta allowed the visualization of the interaction with HepG2 cells in culture, whereas competitive inhibition experiments with unlabeled Abeta demonstrated the specificity of the binding. The capability of the liver to uptake, catabolize, and excrete large doses of Abeta, several orders of magnitude above its physiologic concentration, may explain not only the femtomolar plasma levels of Abeta but the little fluctuation observed with age and disease stages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid degradation of Aβ in the periphery (t1/2 = 2–3 min) precludes a direct and sensitive measurement of the rate of Aβ appearance from brain into blood (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The rapid degradation of Aβ once it enters the blood from brain precludes direct and reliable measurement of its influx rate by conventional means (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The liver clears approximately 60% of circulating Aβ.226”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [226]
Citations
Cites
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Self-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationTargeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Basic and Clinical Pharmacology
Wingard, L. B. (1983) · Anesthesia & Analgesia · doi:10.1213/00000539-198308000-00015 · Cited by 630
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Research works printed but not linked: 5
- Seglen, 1993, Methods Toxicol., 1, 231
- Friedman, 1993, Methods Toxicol., 1, 292
- Baltz, 1985, Clin. Exp. Immunol., 59, 235
- Authier, 1996, Clin. Investig. Med., 19, 149
- Hone, 2003, J. Alz. Dis., 5, 1
Cited by
Items 201–209 of 209
Souchet, B. (2018) · theses.fr (ABES) · doi:10.70675/5510ef76zecf1z41f2z9496z015aa6a093be
Raber, J., & Nielsen, H. M. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_41
Jiang, Q., & Yan-Jiang, W. A. N. G. (2026) · Shengming kexue · doi:10.3724/cbls.2026100
Carrasco, M., Driouech, L., Guzman, L., Barroso, E., Verdaguer, E., Auladell, C., Vázquez‐Carrera, M., Cano, A., Manzine, P. R., Ettcheto, M., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118234
Wang, X., Li, R., Wei, M., & Han, Y. (2026) · European journal of medical research · doi:10.1186/s40001-026-04940-6
“…blood: core amyloid markers (Aβ42, Aβ40, and the Aβ42/Aβ40 ratio, which outperforms individual peptides for amyloid-positivity classification [3, 4], phosphorylated tau species (p-tau181, p-tau217, p-tau231), total tau (t-tau), neurofilament light chain (NfL), and glial fibrillary acidic…”
Reversing liver sinusoidal endothelial aging restores clearance of amyloid-beta and LDL
de Leve, S., Wang, X., Alavifard, H., Dara, L., & DeLeve, L. D. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113608 · Cited by 1
“%) in young, healthy animals (2); when peripheral clearance declines, both peripheral and brain A β increase, demonstrating interdependence between peripheral and central nervous system A β levels (3–8).”
Tianci, M., Yongyi, L., Ding, Y., Liu, S., Gao, C., Li, X., Tong, Z., & Yan, L. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1921485
“The half-life of free unbound A β in peripheral circulation is only 2.5–15 min (Hone et al., 2003; Ghiso et al., 2004), while the free A β concentration in the blood of Alzheimer’s disease (AD) patients is 3–4 times higher than that of healthy individuals (Sagare et al., 2007).”
InfluentialJacquier‐Sarlin, M. R., Seignobos, M., Rauzier, L., Schaack, B., Laurin, D., & Buisson, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1963040
“Once present in the systemic circulation, circulating A β can be taken up by peripheral organs, including the liver and kidneys, which contribute to its metabolism and elimination (Ghiso et al., 2004; Tamaki et al., 2006).”
Metadata
- Authors
- Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B.
- Affiliations
- New York University (US)
- Instituto de Salud Carlos III (ES)
- Corresponding author
- Ghiso, Jorge
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 45897-45908
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2062647232
- Cited by
- 209
- References
- 68
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 5 · 2022: 9 · 2021: 19 · 2020: 15 · 2019: 8 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 11 · 2012: 11
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P01AG010491, AG10491, R01AG008721, AG-08721, AG05891)
- National Institute of Neurological Disorders and Stroke (NS 38777, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- amyloid-beta, Aβ40, amyloid-beta 42, plasma clearance, hepatic uptake, biliary excretion, hepatocytes, peptide oligomerization, peptide conformation, beta-sheet, endocytosis, HepG2 cells, Alzheimer's disease
- MeSH terms
- Amino Acid Sequence, Animals, Bile, Humans, Iodine Radioisotopes, Liver, Male, Molecular Sequence Data, Tissue Distribution, Amyloid beta-Peptides, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.